The Democratic Republic of Congo is confronting a major outbreak of the Bundibugyo strain of Ebola, which the World Health Organization designated a public health emergency on May 17. According to the U.S. Centers for Disease Control and Prevention, the outbreak has produced more than 5,200 confirmed cases and over 2,500 deaths. Congo’s National Public Health Institute reported that more than 550 people were in isolation with Ebola as of Aug. 7. Neighboring Uganda reported 20 cases and two deaths, with no new cases there since June 21, the WHO said.
This is only the third documented outbreak of the Bundibugyo strain in central Africa. Congo officials reported a 44% fatality rate for this strain. There is not yet an approved vaccine for Bundibugyo, and vaccine trials of potential candidates are underway. The outbreak is centered in eastern Congo, where ongoing military conflict has complicated the public health response.
Public health teams in the DRC face multiple barriers beyond the intrinsic severity of Ebola. Misinformation and community distrust have hindered outreach and containment efforts. Armed conflict in eastern provinces has disrupted access to affected communities and constrained safe, timely delivery of care. Travel bans and conflict have also disrupted supply chains, leaving health workers short of tests, protective equipment, and other essential supplies.
According to responders quoted in the source, the international community was already behind in mounting an effective response when awareness of the outbreak expanded. Those delays, combined with the local context, have increased the difficulty of interrupting transmission.
The Africa Centres for Disease Control and Prevention (Africa CDC), the African Union’s public health agency, is coordinating efforts to strengthen detection and response across member states. In collaboration with WHO, Africa CDC announced a joint Ebola response plan on June 5 that emphasizes cross-border communication and a unified “One Response” approach. The organizations estimated they would need more than $500 million over six months to support the plan.
Africa CDC has issued guidance aimed at preventing spread while minimizing undue economic disruption. Their interim guidance recommends targeted measures—such as avoiding contact with bodily fluids—and cautions against blanket travel restrictions to affected areas as a primary control strategy.
Congo’s National Institute for Biomedical Research (INRB), part of the Ministry of Public Health, leads national monitoring and documentation of the virus. INRB teams conduct on-the-ground testing and have established laboratories in Ituri province, the area hardest hit by the outbreak.
The institute has intensified efforts in genomic surveillance—sequencing and analyzing viral genetic material—to track viral evolution. The source describes genomic surveillance as an “essential tool” for containment and for informing vaccine development efforts. The article notes vaccine trials are underway for potential candidates, though no vaccine for Bundibugyo is yet approved.
Doctors Without Borders (MSF) has longstanding operations in Ituri and has deployed personnel to provide emergency medical care, disease surveillance, and treatment in the current outbreak. MSF’s presence in the region spans more than two decades, and the organization has more than 1,400 workers responding to this outbreak.
MSF staff are monitoring patients, ensuring sanitation and infection prevention at treatment centers, and working with partners to distribute resources. MSF leaders cited the organization’s size and financial stability as enabling coordination with regional partners and the reinforcement of existing healthcare programs, including general healthcare services, to prepare for potential additional spread.
Since mid-May, the International Medical Corps (IMC) has been providing case management, community education tailored to the outbreak, and rapid response teams. IMC has established treatment centers for patients and holding centers for people awaiting test results. The organization also supports continuity of primary healthcare in the most at-risk regions to encourage people to continue seeking routine care.
Training local health professionals is a central part of IMC’s strategy; building local capacity is intended to strengthen the ongoing response and leave communities better prepared for future outbreaks. IMC also emphasizes improvements in hygiene and water sanitation and plans to transfer IMC-run facilities to local healthcare leaders over time.
SOFEPADI, a women-led Congolese nonprofit, focuses on women’s and girls’ health and protection from gender-based violence. During Ebola outbreaks, women have historically been overrepresented among deaths due to caregiving roles that increase exposure. SOFEPADI’s work in the current outbreak centers on protecting women because the functioning and resilience of communities are closely tied to women’s health.
The organization highlights that when women fall ill, the broader community suffers, and it implements programs to reduce inequality and support women’s leadership in healthcare decisions.
The article notes international financial and policy responses: the U.S. pledged $512 million in direct aid to address the outbreak and implemented a temporary travel restriction preventing non-U.S. citizens traveling from the affected region from entering the United States. Africa CDC and WHO estimated over $500 million would be needed for the joint continental response over six months.
These funds and policy measures are part of a multipronged effort that includes disease surveillance, clinical care, community engagement, training, and infection prevention. The response aims to interrupt transmission, improve patient care, and build local capacity for future outbreaks.
Responding groups collectively address surveillance and testing, case management, treatment and isolation, community education to counter misinformation, and protection of health workers and vulnerable populations. Key gaps identified in the source include persistent community distrust, supply-chain disruptions for tests and protective gear, and the absence of an approved vaccine specific to the Bundibugyo strain. Genomic surveillance and ongoing vaccine trials are steps toward addressing longer-term prevention but were described as work in progress.
The organizations profiled — Africa CDC, INRB, Doctors Without Borders, International Medical Corps, and SOFEPADI — represent a mix of continental agencies, national research institutions, international NGOs, and local civil society. Together, they combine operational response, scientific monitoring, capacity building, and community support to reduce deaths and limit spread. Specific program budgets, detailed site lists, and outcomes from vaccine trials were not reported in the source.